Display options
Cite
Colizzi M, Ruggeri M, Bhattacharyya S. Unraveling the Intoxicating and Therapeutic Effects of Cannabis Ingredients on Psychosis and Cognition. Front Psychol. 2020;11:833doi: 10.3389/fpsyg.2020.00833.
Colizzi, M., Ruggeri, M., & Bhattacharyya, S. (2020). Unraveling the Intoxicating and Therapeutic Effects of Cannabis Ingredients on Psychosis and Cognition. Frontiers in psychology, 11833. https://doi.org/10.3389/fpsyg.2020.00833
Colizzi, Marco, et al. "Unraveling the Intoxicating and Therapeutic Effects of Cannabis Ingredients on Psychosis and Cognition." Frontiers in psychology vol. 11 (2020): 833. doi: https://doi.org/10.3389/fpsyg.2020.00833
Colizzi M, Ruggeri M, Bhattacharyya S. Unraveling the Intoxicating and Therapeutic Effects of Cannabis Ingredients on Psychosis and Cognition. Front Psychol. 2020 May 14;11:833. doi: 10.3389/fpsyg.2020.00833. eCollection 2020. PMID: 32528345; PMCID: PMC7247841.
Copy Download .nbib Format: NLM
Share it on

Front Psychol. 2020 May 14;11:833. doi: 10.3389/fpsyg.2020.00833. eCollection 2020.

Unraveling the Intoxicating and Therapeutic Effects of Cannabis Ingredients on Psychosis and Cognition.

Frontiers in psychology

Marco Colizzi, Mirella Ruggeri, Sagnik Bhattacharyya

Affiliations

  1. Section of Psychiatry, Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy.
  2. Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom.

PMID: 32528345 PMCID: PMC7247841 DOI: 10.3389/fpsyg.2020.00833

Abstract

Research evidence suggests a dose-response relationship for the association between cannabis use and risk of psychosis. Such relationship seems to reflect an increased risk of psychosis not only as a function of frequent cannabis use, but also of high-potency cannabis use in terms of concentration of Δ-9-tetrahydrocannabinol (Δ9-THC), its main psychoactive component. This finding would be in line with the evidence that Δ9-THC administration induces transient psychosis-like symptoms in otherwise healthy individuals. Conversely, low-potency varieties would be less harmful because of their lower amount of Δ9-THC and potential compresence of another cannabinoid, cannabidiol (CBD), which seems to mitigate Δ9-THC detrimental effects. A growing body of studies begins to suggest that CBD may have not only protective effects against the psychotomimetic effects of Δ9-THC but even therapeutic properties on its own, opening new prospects for the treatment of psychosis. Despite being more limited, evidence of the effects of cannabis on cognition seems to come to similar conclusions, with increasing Δ9-THC exposure being responsible for the cognitive impairments attributed to recreational cannabis use while CBD preventing such effects and, when administered alone, enhancing cognition. Molecular evidence indicates that Δ9-THC and CBD may interact with cannabinoid receptors with almost opposite mechanisms, with Δ9-THC being a partial agonist and CBD an inverse agonist/antagonist. With the help of imaging techniques, pharmacological studies

Copyright © 2020 Colizzi, Ruggeri and Bhattacharyya.

Keywords: cannabidiol; cognition; endocannabinoid system; psychosis; Δ-9-tetrahydrocannabinol

References

  1. JAMA Psychiatry. 2016 Nov 1;73(11):1173-1179 - PubMed
  2. Schizophr Res. 2016 Mar;171(1-3):62-7 - PubMed
  3. Arch Gen Psychiatry. 2012 Jan;69(1):27-36 - PubMed
  4. Psychol Med. 2018 Oct;48(14):2346-2352 - PubMed
  5. Psychopharmacology (Berl). 2002 Oct;164(1):61-70 - PubMed
  6. Br J Psychiatry. 2006 Jun;188:519-26 - PubMed
  7. Exp Clin Psychopharmacol. 2018 Dec;26(6):582-598 - PubMed
  8. Nat Prod Rep. 2016 Nov 23;33(12):1357-1392 - PubMed
  9. Biol Psychiatry. 2005 Mar 15;57(6):594-608 - PubMed
  10. Am J Epidemiol. 2002 Aug 15;156(4):319-27 - PubMed
  11. Mol Psychiatry. 2012 Dec;17(12):1152-5 - PubMed
  12. Schizophr Bull. 2016 Sep;42(5):1262-9 - PubMed
  13. Psychol Med. 2014 Dec;44(16):3435-44 - PubMed
  14. Drug Alcohol Depend. 2014 Nov 1;144:12-41 - PubMed
  15. J Neurosci. 2019 Oct 16;39(42):8250-8258 - PubMed
  16. PLoS One. 2013 Oct 24;8(10):e76635 - PubMed
  17. JAMA Psychiatry. 2018 Nov 1;75(11):1107-1117 - PubMed
  18. J Psychopharmacol. 2009 Nov;23(8):979-83 - PubMed
  19. J Addict Res Ther. 2013 Apr 24;Suppl 4: - PubMed
  20. Hum Psychopharmacol. 2013 Jul;28(4):379-89 - PubMed
  21. Proc Natl Acad Sci U S A. 2016 Feb 2;113(5):E500-8 - PubMed
  22. BMC Neurosci. 2012 Feb 15;13:18 - PubMed
  23. Front Psychiatry. 2019 Feb 19;10:63 - PubMed
  24. J Clin Psychiatry. 1995 Oct;56(10):485-6 - PubMed
  25. BMJ. 2002 Nov 23;325(7374):1212-3 - PubMed
  26. Neurotherapeutics. 2015 Oct;12(4):699-730 - PubMed
  27. Neuropsychopharmacology. 2015 May;40(6):1343-52 - PubMed
  28. Br J Pharmacol. 2008 Jan;153(2):199-215 - PubMed
  29. Eur Neuropsychopharmacol. 2015 Jan;25(1):26-37 - PubMed
  30. Lancet. 1987 Dec 26;2(8574):1483-6 - PubMed
  31. Psychol Med. 2016 Mar;46(4):841-54 - PubMed
  32. BMJ. 2019 Apr 4;365:l1141 - PubMed
  33. Lancet Psychiatry. 2015 Mar;2(3):233-8 - PubMed
  34. Eur Neuropsychopharmacol. 2018 Jul;28(7):850-862 - PubMed
  35. Psychopharmacology (Berl). 2019 Dec 9;: - PubMed
  36. Exp Clin Psychopharmacol. 2012 Oct;20(5):420-429 - PubMed
  37. Int J Mol Sci. 2018 Mar 13;19(3): - PubMed
  38. Eur Neuropsychopharmacol. 2015 Mar;25(3):325-34 - PubMed
  39. Neurosci Biobehav Rev. 2018 May;88:26-41 - PubMed
  40. Biol Psychiatry. 2016 Apr 1;79(7):595-603 - PubMed
  41. Philos Trans R Soc Lond B Biol Sci. 2012 Dec 5;367(1607):3216-28 - PubMed
  42. Brain Sci. 2019 Apr 25;9(4): - PubMed
  43. Br J Pharmacol. 2015 Oct;172(20):4790-805 - PubMed
  44. Biol Psychiatry. 2016 Apr 1;79(7):516-25 - PubMed
  45. Curr Pharm Des. 2012;18(32):5045-54 - PubMed
  46. Addiction. 2012 Jun;107(6):1174-84 - PubMed
  47. Addiction. 2005 May;100(5):612-8 - PubMed
  48. Psychopharmacology (Berl). 2018 Jul;235(7):1923-1932 - PubMed
  49. Braz J Psychiatry. 2019 Jan-Mar;41(1):9-14 - PubMed
  50. Psychol Med. 2018 Dec;48(16):2748-2756 - PubMed
  51. Physiol Rev. 2009 Jan;89(1):309-80 - PubMed
  52. Br J Psychiatry. 2010 Oct;197(4):285-90 - PubMed
  53. J Psychopharmacol. 2006 Sep;20(5):683-6 - PubMed
  54. BMJ. 2002 Nov 23;325(7374):1199 - PubMed
  55. Neuropharmacology. 2017 Sep 15;124:89-104 - PubMed
  56. Psychol Med. 2003 Jan;33(1):15-21 - PubMed
  57. Nat Rev Neurosci. 2015 Jan;16(1):30-42 - PubMed
  58. Nature. 1993 Sep 2;365(6441):61-5 - PubMed
  59. Schizophr Res. 2015 Oct;168(1-2):185-90 - PubMed
  60. Addict Biol. 2019 Sep 2;:e12827 - PubMed
  61. Psychol Med. 2014 Nov;44(15):3315-28 - PubMed
  62. Br J Psychiatry. 2018 Apr;212(4):195-196 - PubMed
  63. JAMA Psychiatry. 2018 Jun 1;75(6):585-595 - PubMed
  64. Br J Pharmacol. 2007 Mar;150(5):613-23 - PubMed
  65. Br J Psychiatry. 2010 Jun;196(6):447-53 - PubMed
  66. Biochem Pharmacol. 1995 Jun 29;50(1):83-90 - PubMed
  67. Front Immunol. 2018 Sep 21;9:2009 - PubMed
  68. J Psychopharmacol. 2016 Feb;30(2):140-51 - PubMed
  69. Lancet Psychiatry. 2016 Oct;3(10):947-953 - PubMed
  70. Neurobiol Aging. 2005 May;26(5):665-72 - PubMed
  71. Science. 1992 Dec 18;258(5090):1946-9 - PubMed
  72. JAMA Psychiatry. 2013 Jan;70(1):107-20 - PubMed
  73. JAMA Psychiatry. 2019 Jun 5;: - PubMed
  74. Br J Pharmacol. 2007 Nov;152(5):583-93 - PubMed
  75. Eur Neuropsychopharmacol. 2015 Aug;25(8):1201-24 - PubMed
  76. Am J Psychiatry. 2016 Aug 1;173(8):781-9 - PubMed
  77. Sci Rep. 2017 Nov 3;7(1):15025 - PubMed
  78. Neuropsychopharmacology. 2010 Feb;35(3):764-74 - PubMed
  79. Transl Psychiatry. 2019 Aug 22;9(1):203 - PubMed
  80. Proc Natl Acad Sci U S A. 2012 Oct 2;109(40):E2657-64 - PubMed
  81. JAMA Psychiatry. 2017 Jun 1;74(6):579-588 - PubMed
  82. Expert Opin Emerg Drugs. 2009 Mar;14(1):43-65 - PubMed
  83. Curr Addict Rep. 2017;4(2):62-74 - PubMed
  84. Mol Psychiatry. 2019 Feb 15;: - PubMed
  85. Front Public Health. 2018 Jun 07;6:162 - PubMed
  86. Neurosci Biobehav Rev. 2019 Jan;96:45-55 - PubMed
  87. F1000 Med Rep. 2013;5:1 - PubMed
  88. Am J Psychiatry. 2004 Jun;161(6):975-84 - PubMed
  89. Curr Drug Abuse Rev. 2012 Mar;5(1):32-40 - PubMed
  90. BMJ. 2005 Jan 1;330(7481):11 - PubMed
  91. Psychol Med. 2019 Aug 19;:1-10 - PubMed
  92. J Psychopharmacol. 2010 Jan;24(1):135-7 - PubMed
  93. Molecules. 2018 May 20;23(5): - PubMed
  94. Addiction. 2016 Oct;111(10):1764-73 - PubMed
  95. JAMA. 2015 Jun 23-30;313(24):2456-73 - PubMed
  96. Lancet Psychiatry. 2019 Dec;6(12):995-1010 - PubMed
  97. Neuropsychopharmacology. 2004 Aug;29(8):1558-72 - PubMed
  98. Braz J Psychiatry. 2010 Mar;32(1):56-61 - PubMed
  99. Neurosci Biobehav Rev. 2018 Oct;93:1-25 - PubMed
  100. Br J Pharmacol. 2015 Feb;172(3):737-53 - PubMed
  101. Drug Metab Rev. 2018 Feb;50(1):3-13 - PubMed
  102. Biol Psychiatry. 2016 Apr 1;79(7):539-48 - PubMed
  103. MMWR Morb Mortal Wkly Rep. 2015 Jun 12;64(22):618-9 - PubMed
  104. Am J Med Genet. 2002 Dec 8;114(8):949-55 - PubMed
  105. J Nerv Ment Dis. 1990 Aug;178(8):473-80 - PubMed
  106. Ther Adv Psychopharmacol. 2019 Nov 08;9:2045125319881916 - PubMed
  107. Br J Psychiatry. 2015 Jan;206(1):77-8 - PubMed
  108. Neurosci Biobehav Rev. 2016 May;64:359-81 - PubMed
  109. J Neuroimmune Pharmacol. 2018 Dec;13(4):438-452 - PubMed
  110. Lancet. 2018 Nov 10;392(10159):1923-1994 - PubMed
  111. Psychol Med. 2020 Jan 29;:1-11 - PubMed
  112. Nat Med. 2017 Jun;23(6):782-787 - PubMed
  113. Curr Psychiatry Rep. 2016 Feb;18(2):12 - PubMed
  114. Neurotherapeutics. 2015 Oct;12(4):735-46 - PubMed
  115. Exp Clin Psychopharmacol. 2019 Oct 31;: - PubMed
  116. Lancet Psychiatry. 2019 May;6(5):427-436 - PubMed
  117. Psychopharmacology (Berl). 2020 Apr;237(4):1121-1130 - PubMed
  118. Prog Brain Res. 2018;242:179-216 - PubMed
  119. Schizophr Res. 2016 Feb;170(2-3):311-7 - PubMed
  120. Cortex. 2016 Aug;81:231-8 - PubMed
  121. J Psychopharmacol. 2015 Feb;29(2):97-115 - PubMed
  122. Eur Arch Psychiatry Clin Neurosci. 2019 Feb;269(1):17-35 - PubMed
  123. Psychol Med. 2012 Feb;42(2):391-400 - PubMed
  124. Am J Psychiatry. 2018 Mar 1;175(3):225-231 - PubMed
  125. Curr Pharm Des. 2016;22(42):6380-6391 - PubMed
  126. Psychol Med. 2016 Jan;46(1):177-88 - PubMed
  127. Transl Psychiatry. 2012 Mar 20;2:e94 - PubMed
  128. Arch Gen Psychiatry. 2009 Apr;66(4):442-51 - PubMed
  129. Psychol Med. 2012 Jun;42(6):1321-8 - PubMed
  130. Nature. 1990 Aug 9;346(6284):561-4 - PubMed

Publication Types

Grant support